In this case report, the authors present a patient with metastatic pulmonary epithelioid hemangioendothelioma (EHE). EHE is a rare vascular tumor of intermediate malignancy that occurs most commonly in the liver, lung, soft tissue, or bone. The primary treatment of localized disease is surgical resection. However, when the primary disease is unresectable or metastatic at diagnosis, systemic therapy can be considered. The authors describe their patient, a 62-year-old woman with symptomatic chest pain who is found to have metastatic pulmonary EHE. The patient was treated with pazopanib with a partial, durable response of more than 2 years and minimal toxicity. This is an interesting case report and adds to the literature regarding systemic therapy options for EHE. I would recommend the following revisions prior to acceptance and publication.

Major compulsory revisions:

1. In the abstract, in the case presentation section, the authors mention that the patient had partial response of her disease. What criteria were used to determine partial disease response? In the CT images provided (figure 2), the lung nodules look fairly stable. If the patient had stable disease by RECIST, the words “partial response” should be removed.

2. In the body of the manuscript, in the case presentation section, I would discuss the rationale for following tumor response by PET-CT. Disease response assessment in soft tissue sarcoma is generally done with CT/MRI imaging using RECIST criteria.

3. The review of antiangiogenic treatment options in the discussion needs to be strengthened. I would include a discussion of 2 additional studies: a phase II study of bevacizumab in EHE and angiosarcoma which included 7 patients with EHE (2PR, 4SD) (Ann Oncol 2013;24(1):257-63.) and the phase 2 French Sarcoma group study using Sorafenib in 15 patients with EHE (12 with lung metastases) (Cancer 2013;15;119(14):2639-44.). There was also another case study of long-term response to lenalidomide in hepatic EHE that could be included (World J Gastroenterol 2014 Jun 14;20(22):7049-54).

Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare I have no competing interests.